| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $0 ) |
| | 2024 | 2022 | AVEXEGEN THERAPEUTICS INC. | 20369 VIA CELLINI | PORTER RANCH | CA | 91326-4061 | LOS ANGELES | USA | R44DK112435 | Neuregulin-4: A Novel Therapy for Inflammatory Bowel Disease | 001 | 3 | NIH | 8/25/2024 | $0 |
| | 2024 | 2022 | AVEXEGEN THERAPEUTICS INC. | 20369 VIA CELLINI | PORTER RANCH | CA | 91326-4061 | LOS ANGELES | USA | R44DK112435 | Neuregulin-4: A Novel Therapy for Inflammatory Bowel Disease | 000 | 3 | NIH | 1/30/2024 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $2,074,215 ) |
| | 2022 | 2022 | AVEXEGEN THERAPEUTICS INC. | 20369 VIA CELLINI | PORTER RANCH | CA | 91326-4061 | LOS ANGELES | USA | R44DK112435 | Neuregulin-4: A Novel Therapy for Inflammatory Bowel Disease | 000 | 3 | NIH | 1/11/2022 | $1,866,793 |
| | 2022 | 2022 | AVEXEGEN THERAPEUTICS INC. | 20369 VIA CELLINI | PORTER RANCH | CA | 91326-4061 | LOS ANGELES | USA | R44DK112435 | Neuregulin-4: A Novel Therapy for Inflammatory Bowel Disease | 001 | 3 | NIH | 1/19/2022 | $207,422 |
|
| Issue Date FY: 2021 ( Subtotal = $867,924 ) |
| | 2021 | 2021 | AVEXEGEN THERAPEUTICS INC. | 388 MARKET STREET SUITE 1300 | SAN FRANCISCO | CA | 94111-5316 | SAN FRANCISCO | USA | R44DK112435 | Neuregulin-4: A Novel Therapy for Inflammatory Bowel Disease | 000 | 2 | NIH | 2/3/2021 | $867,924 |
|
| Issue Date FY: 2019 ( Subtotal = $0 ) |
| | 2019 | 2016 | AVEXEGEN THERAPEUTICS INC | 388 MARKET STREET SUITE 1300 | SAN FRANCISCO | CA | 94111-5316 | SAN FRANCISCO | USA | R43DK112435 | Neuregulin-4: A Novel Therapy for Inflammatory Bowel Disease | 000 | 1 | NIH | 9/26/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $0 ) |
| | 2018 | 2016 | AVEXEGEN THERAPEUTICS INC | 388 MARKET STREET SUITE 1300 | SAN FRANCISCO | CA | 94111-5316 | SAN FRANCISCO | USA | R43DK112435 | Neuregulin-4: A Novel Therapy for Inflammatory Bowel Disease | 000 | 1 | NIH | 9/7/2018 | $0 |
|
| Issue Date FY: 2016 ( Subtotal = $225,000 ) |
| | 2016 | 2016 | AVEXEGEN THERAPEUTICS INC | 388 MARKET STREET | SAN FRANCISCO | CA | 94111 | SAN FRANCISCO | USA | R43DK112435 | Neuregulin-4: A Novel Therapy for Inflammatory Bowel Disease | 000 | 1 | NIH | 9/16/2016 | $225,000 |
|
|
